Status | Study |
Recruiting |
Study Name: Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo Condition: Erysipelas Impetigo Herpes Zo Date: 2016-09-08 Interventions: Procedure: Screening |
Active, not recruiting |
Study Name: Azithromycin - Ivermectin Mass Drug Administration for Skin Disease Condition: Scabies Yaws Impetigo Date: 2016-02-24 Interventions: Drug: Ivermectin Participants |
Completed |
Study Name: Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo Condition: Impetigo Date: 2014-03-17 Interventions: Drug: Ozenoxacin Drug: Placebo |
Completed |
Study Name: The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial Condition: Impetigo Date: 2013-08-30 Interventions: Drug: papaya 1% extract ointment Drug: mup |
Completed |
Study Name: A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo Condition: Non-bullous Impetigo Date: 2013-02-21 Interventions: Drug: LTX-109 1 % Drug: LTX-109 2 % |
Completed |
Study Name: Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo Condition: Impetigo Date: 2012-08-17 Interventions: Drug: Experimental: CD07223 1.5 % Topical Gel BID |
Completed |
Study Name: Citriodiol® and Impetigo Condition: Impetigo Date: 2012-05-29 Interventions: Drug: p-menthane-3,8-diol oil Apply topically to affected area twice daily |
Completed |
Study Name: ALTARGO(Retapamulin) PMS(Post-marketing Surveillance) Condition: Skin Infections, Bacterial Date: 2011-09-21 Interventions: Drug: ALTARGO(retapamulin) Basically there is no treatment allocation. Subjects who would be administere |
Completed |
Study Name: Safety and Efficacy of Topical NVC-422 Gel in Impetigo Condition: Impetigo Date: 2011-06-03 Interventions: Drug: NVC-422 Dermal Gel applied 3 times per day for 7 days |
Completed |
Study Name: A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection Condition: Gram-positive, Skin Infections Mild Eczema/Dermatoses Atop Date: 2010-10-14 Interventions: Drug: LTX-109 Topical administration. 3 times daily. 5 days. |